Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF) T. Takaiwa, H. Tachibana, M. Arita, T. Ishida (Kurashiki, Japan)
Source: International Congress 2014 – ILDs 3
Session: ILDs 3 Session type: Thematic Poster Session Number: 785
Disease area: Interstitial lung diseasesAbstract Background:Pirfenidone has been used for the treatment of IPF in Japan since 2008. However, the long term efficacy of the drug remains unclear.Purpose:To evaluate the efficacy of pirfenidone therapy for ³ 6 months and identify the predictive factors for drug responseMethods:Between July 2010 and August 2013, 38 patients underwent pirfenidone therapy for clinico-radiologically diagnosed IPF based on an official ATS/ERS/JRS/ALAT statement published in 2011. We evaluated the efficacy on the chronological changes of percent forced vital capacity (%FVC), percent diffusing capacity for carbon monoxide (%DLCO), and composite physiologic index (CPI). Patients were divided into two groups; patients who continued the therapy for ³ 6 months, tolerable group, and patients who withdrew the therapy, intolerable group. We investigated baseline characteristics between two groups.Results:Twenty-five patients continued the therapy for ³ 6 months. In the tolerable group, the mean changes of %FVC were -2.872% (-6-0month), +2.565% (0-6months), -1.017% (6-12months), and -6.398% (12-18months), and the mean changes of %DLCO and CPI were similar.In the same group, linear mixed-effects model analysis showed that pirfenidone significantly improved %FVC at 6 months, %DLCO at 6 and 12 months, and CPI at 6 and 12 months. In the tolerable group, the baseline %FVC and %DLCO were significantly higher (p=0.004, 0.033 respectively), and the baseline CPI was significantly lower (p=0.011) than in the intolerable group.Conclusion:Our results suggest that pirfenidone is effective for 12 months but ineffective at 18 months and that drug response is better in patients with good pulmonary function on the baseline.Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Takaiwa, H. Tachibana, M. Arita, T. Ishida (Kurashiki, Japan). Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF). Eur Respir J 2014; 44: Suppl. 58, 785
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: